Body fat and waist size linked to increased risk of developing rheumatoid arthritis in women
Madrid, Spain, 14 June 2017:
The results of a population study presented today at the Annual European Congress of Rheumatology (EULAR) 2017 showed that, in women, being overweight or obese, as defined by body mass index (BMI*), abdominal obesity and a higher body fat percentage was associated with a higher risk of developing rheumatoid arthritis (RA).1
However, there was no clear association between the risk of RA and the different criteria that define being overweight or obese in men.1
Previous studies investigating the association between being overweight and the development of RA have come out with conflicting results about the link between BMI and the risk of RA.2,3,4,5
“One possible explanation for these inconsistencies is that while BMI has been the preferred surrogate measure for being overweight in these studies, BMI only correlates modestly with total amount of body fat and does not accurately reflect fat distribution,” said lead author Dr. Asta Linauskas from University Hospital, Aarhus, Denmark. “Our results support an association between the risk of developing RA and three different criteria for being overweight or obese in women. We believe RA should be included in the list of all the other medical conditions linked to obesity. It would certainly make sense for women with a family history of RA to try to avoid becoming overweight,” she added.
In women, the hazard ratio† for a BMI of 25-29.99 kg/m2 (considered overweight) was 1.48 (95 % CI‡ 1.14-1.91), and for a BMI >30 kg/m2 (considered obese) was 1.54 (1.09-2.17). For abdominal obesity, defined in women as a waist circumference >88 cm, the hazard ratio was 1.24 (0.96-1.61). For each 1% higher body fat percentage, in women the hazard ratio was 1.03 (1.01-1.05).
In men, the hazard ratio for a BMI of 25-29.99 kg/m2 was 0.83 (0.55-1.24), and for a BMI >30 kg/m2 was 0.69 (0.37-1.30). For abdominal obesity, defined in men as a waist circumference >102 cm, the hazard ratio was 1.16 (0.75-1.80). For each 1% higher body fat percentage, in men the hazard ratio was 0.99 (0.96-1.03).
To further define the relationship between body fat percentage and the risk of developing RA, a “restricted cubic spline§” statistical analysis was performed. A positive slope in women confirmed a direct relationship; however, there was no such linear association in men.
From a population of 54,284 subjects (52% female), aged between 50 and 64 years at the time of recruitment between 1993 and 1997, 283 women and 110 men developed RA during a median follow-up period of 21 years. The median time to onset of RA was 7 (interquartile range of 4-11) years.
Body fat composition measurements and data on lifestyle factors were collected at enrolment. The participants were followed until development of RA, death, loss to follow-up or October 2016, whichever came first. The participants who developed RA were identified through linkage to The Danish National Patient Registry.
Hazard ratios were adjusted for potential confounding from age, smoking status, total tobacco consumption (g/day), smoking duration, alcohol consumption (g/day), socio-economic status, physical activity (based on a formula that calculates the energy expenditure of different physical activities), and total intake of n-3 fatty acids.
Abstract Number: OP0079
* an approximate measure of whether someone is over- or underweight, calculated by dividing their weight in kilograms by the square of their height in metres
† A hazard ratio greater than 1.0 infers a direct association, the higher the figure the stronger the association
‡ 95% Confidence Interval infers that there is a 95% chance that the actual hazard ratio is between the two figures given
§ statistical method of estimating the relationship between two or more variables that allows for a non-linear relationship
1 Linauskas A, de Thurah AL, Overvad K, et al. Body fat percentage and waist circumference were associated with the development of rheumatoid arthritis – a Danish follow-up study. EULAR 2017; Madrid: Abstract OP0079
2 Qin B, Yang M, Fu H, et al. Body mass index and the risk of rheumatoid arthritis: a systematic review and dose-response meta-analysis. Arthritis Research & Therapy. 2015;17(1):86
3 Cerhan JR, Saag KG, Criswell LA, et al. Blood transfusion, alcohol use, and anthropometric risk factors for rheumatoid arthritis in older women. J Rheumatol. 2002; 29 (2): 246-54
4 Rodríguez LA, Tolosa LB, Ruigómez A, et al. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. Scand J Rheumatol. 2009; 38 (3): 173-7
5 Wesley A, Bengtsson C, Elkan AC, et al; Epidemiological Investigation of Rheumatoid Arthritis Study Group. Association between body mass index and anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis: results from a population-based case-control study. Arthritis Care Res (Hoboken). 2013; 65 (1): 107-12
Related news and insights
Pfizer Inc. announced that the FDA has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for Abrilada (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab).
Olumiant (baricitinib) from Eli Lilly and Incyte, maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received Olumiant for 14,744 patient years of exposure, in line with previously published findings.